MSK in the News: December 26 – January 5

  • Memorial Sloan-Kettering has received a $90 million donation as a share of an unprecedented $540 million gift from the Ludwig Cancer Research organization, to 6 prestigious academic institutions.  Memorial will use the funds to support research in immuno-oncology – fighting cancer using the immune system.
  • MSKCC’s Dr. Michael Mauro is pleased that the FDA is allowing sale of the leukemia drug, Iclusig, to resume after it had been taken off the market.
  • Dr. Tim Ahles of MSKCC commented on the phenomenon of premature aging in adult survivors of childhood cancers.

The Globocan Project: A Reputable Source of Cancer Facts and Statistics

The Globocan Project is updated annually with cancer estimates and statistics from the previous year in the following areas: incidence, mortality, and prevalence. Information from 2012 is currently available.

Information is separated by sex and cancer type, with prevalence figures spanning either 1-, 3-, or 5-years. One strength of The Globocan Project is its’ worldwide scope with stats from 184 countries in the world. The resource comes from the World Health Organization’s (WHO) International Agency for Research on Cancer, so it’s no surprise that the data sources and methods are readily available for users. This transparency makes it easy to understand how and where the data is gathered.

Content-wise, The Globocan Project contains fact sheets broken down by cancer type and population, maps and atlases, cancer predictions, and a section for further analysis of data online. The output generated from the analysis section ranges from simple lists of information to charts, figures, and graphs. 

To learn more about this resource or other stat-related resources, don’t hesitate to Ask-a-Librarian!